Simultaneous	O
quantification	O
of	O
isoniazid	B:C0022209
,	O
rifampicin	O
,	O
ethambutol	O
and	O
pyrazinamide	O
by	O
liquid	O
chromatography	I:C0008565
/	O
tandem	O
mass	O
spectrometry	O
.	O

Simultaneous	O
quantification	O
of	O
isoniazid	O
,	O
rifampicin	B:C0035608
,	O
ethambutol	O
and	O
pyrazinamide	O
by	O
liquid	O
chromatography	I:C0008565
/	O
tandem	O
mass	O
spectrometry	O
.	O

Simultaneous	O
quantification	O
of	O
isoniazid	O
,	O
rifampicin	O
,	O
ethambutol	B:C0014964
and	O
pyrazinamide	O
by	O
liquid	O
chromatography	I:C0008565
/	O
tandem	O
mass	O
spectrometry	O
.	O

Simultaneous	O
quantification	O
of	O
isoniazid	O
,	O
rifampicin	O
,	O
ethambutol	O
and	O
pyrazinamide	B:C0034239
by	O
liquid	O
chromatography	I:C0008565
/	O
tandem	O
mass	O
spectrometry	O
.	O

Simultaneous	O
quantification	O
of	O
isoniazid	O
,	O
rifampicin	O
,	O
ethambutol	O
and	O
pyrazinamide	O
by	O
liquid	B:C0008565
chromatography	I:C0008565
/	O
tandem	O
mass	O
spectrometry	O
.	O

A	O
remediable	B:C1709895
cause	O
of	O
poor	O
treatment	I:C1320680
response	I:C1320680
in	O
drug	O
-	O
susceptible	O
tuberculosis	O
(	O
tuberculosis	O
)	O
patients	O
may	O
be	O
low	O
plasma	O
levels	O
of	O
one	O
or	O
more	O
of	O
the	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
.	O

A	O
remediable	O
cause	O
of	O
poor	B:C1320680
treatment	I:C1320680
response	I:C1320680
in	O
drug	O
-	O
susceptible	O
tuberculosis	O
(	O
tuberculosis	O
)	O
patients	O
may	O
be	O
low	O
plasma	O
levels	O
of	O
one	O
or	O
more	O
of	O
the	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
.	O

A	O
remediable	O
cause	O
of	O
poor	O
treatment	I:C1320680
response	I:C1320680
in	O
drug	B:C1254351
-	O
susceptible	O
tuberculosis	O
(	O
tuberculosis	O
)	O
patients	O
may	O
be	O
low	O
plasma	O
levels	O
of	O
one	O
or	O
more	O
of	O
the	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
.	O

A	O
remediable	O
cause	O
of	O
poor	O
treatment	I:C1320680
response	I:C1320680
in	O
drug	O
-	O
susceptible	O
tuberculosis	B:C0041296
(	O
tuberculosis	O
)	O
patients	O
may	O
be	O
low	O
plasma	O
levels	O
of	O
one	O
or	O
more	O
of	O
the	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
.	O

A	O
remediable	O
cause	O
of	O
poor	O
treatment	I:C1320680
response	I:C1320680
in	O
drug	O
-	O
susceptible	O
tuberculosis	O
(	O
tuberculosis	B:C0041296
)	O
patients	O
may	O
be	O
low	O
plasma	O
levels	O
of	O
one	O
or	O
more	O
of	O
the	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
.	O

A	O
remediable	O
cause	O
of	O
poor	O
treatment	I:C1320680
response	I:C1320680
in	O
drug	O
-	O
susceptible	O
tuberculosis	O
(	O
tuberculosis	O
)	O
patients	O
may	O
be	O
low	O
plasma	B:C0032105
levels	O
of	O
one	O
or	O
more	O
of	O
the	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
.	O

A	O
remediable	O
cause	O
of	O
poor	O
treatment	I:C1320680
response	I:C1320680
in	O
drug	O
-	O
susceptible	O
tuberculosis	O
(	O
tuberculosis	O
)	O
patients	O
may	O
be	O
low	O
plasma	O
levels	O
of	O
one	O
or	O
more	O
of	O
the	O
first	O
-	O
line	O
anti-TB	B:C0003237
drugs	I:C0003237
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
develop	O
an	O
accurate	O
and	O
precise	O
LC	B:C0872318
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
for	O
simultaneous	O
quantification	O
of	O
all	O
four	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	O
suitable	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
(	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
)	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
develop	O
an	O
accurate	O
and	O
precise	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	B:C0037813
method	O
for	O
simultaneous	O
quantification	O
of	O
all	O
four	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	O
suitable	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
(	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
)	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
develop	O
an	O
accurate	O
and	O
precise	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
for	O
simultaneous	O
quantification	O
of	O
all	O
four	O
first	O
-	O
line	O
anti-TB	B:C0003237
drugs	I:C0003237
in	O
plasma	O
suitable	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
(	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
)	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
develop	O
an	O
accurate	O
and	O
precise	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
for	O
simultaneous	O
quantification	O
of	O
all	O
four	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	B:C0032105
suitable	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
(	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
)	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
develop	O
an	O
accurate	O
and	O
precise	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
for	O
simultaneous	O
quantification	O
of	O
all	O
four	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	O
suitable	O
for	O
therapeutic	B:C1720825
drug	I:C1720825
monitoring	I:C1720825
(	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
)	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
develop	O
an	O
accurate	O
and	O
precise	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
for	O
simultaneous	O
quantification	O
of	O
all	O
four	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	O
suitable	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
(	O
therapeutic	B:C1720825
drug	I:C1720825
monitoring	I:C1720825
)	O
.	O

To	O
adjust	O
for	O
degradation	O
and	O
losses	O
during	O
sample	O
preparation	O
,	O
isotopically	B:C0022262
labeled	I:C0022262
compounds	I:C0022262
were	O
used	O
as	O
internal	O
standards	O
.	O

Plasma	B:C0444263
samples	I:C0444263
spiked	O
with	O
internal	O
standards	O
were	O
extracted	O
using	O
protein	O
precipitation	I:C3815102
with	O
methanol	O
and	O
acetonitrile	O
.	O

Plasma	O
samples	I:C0444263
spiked	O
with	O
internal	O
standards	O
were	O
extracted	B:C0022885
using	O
protein	O
precipitation	I:C3815102
with	O
methanol	O
and	O
acetonitrile	O
.	O

Plasma	O
samples	I:C0444263
spiked	O
with	O
internal	O
standards	O
were	O
extracted	O
using	O
protein	B:C3815102
precipitation	I:C3815102
with	O
methanol	O
and	O
acetonitrile	O
.	O

Plasma	O
samples	I:C0444263
spiked	O
with	O
internal	O
standards	O
were	O
extracted	O
using	O
protein	O
precipitation	I:C3815102
with	O
methanol	B:C0001963
and	O
acetonitrile	O
.	O

Plasma	O
samples	I:C0444263
spiked	O
with	O
internal	O
standards	O
were	O
extracted	O
using	O
protein	O
precipitation	I:C3815102
with	O
methanol	O
and	O
acetonitrile	B:C0050456
.	O

Simultaneous	O
separation	O
of	O
all	O
four	O
drugs	B:C0013227
was	O
accomplished	O
with	O
a	O
Chromolith	O
Reversed	O
-	O
Phase	O
column	O
and	O
mobile	O
phases	I:C3469601
consisting	O
of	O
water	O
,	O
methanol	O
,	O
ammonium	O
acetate	I:C0051704
and	O
formic	O
acid	I:C0016576
with	O
subsequent	O
mass	O
spectrometric	O
quantification	O
.	O

Simultaneous	O
separation	O
of	O
all	O
four	O
drugs	O
was	O
accomplished	O
with	O
a	O
Chromolith	O
Reversed	O
-	O
Phase	O
column	O
and	O
mobile	B:C3469601
phases	I:C3469601
consisting	O
of	O
water	O
,	O
methanol	O
,	O
ammonium	O
acetate	I:C0051704
and	O
formic	O
acid	I:C0016576
with	O
subsequent	O
mass	O
spectrometric	O
quantification	O
.	O

Simultaneous	O
separation	O
of	O
all	O
four	O
drugs	O
was	O
accomplished	O
with	O
a	O
Chromolith	O
Reversed	O
-	O
Phase	O
column	O
and	O
mobile	O
phases	I:C3469601
consisting	O
of	O
water	B:C0043047
,	O
methanol	O
,	O
ammonium	O
acetate	I:C0051704
and	O
formic	O
acid	I:C0016576
with	O
subsequent	O
mass	O
spectrometric	O
quantification	O
.	O

Simultaneous	O
separation	O
of	O
all	O
four	O
drugs	O
was	O
accomplished	O
with	O
a	O
Chromolith	O
Reversed	O
-	O
Phase	O
column	O
and	O
mobile	O
phases	I:C3469601
consisting	O
of	O
water	O
,	O
methanol	B:C0001963
,	O
ammonium	O
acetate	I:C0051704
and	O
formic	O
acid	I:C0016576
with	O
subsequent	O
mass	O
spectrometric	O
quantification	O
.	O

Simultaneous	O
separation	O
of	O
all	O
four	O
drugs	O
was	O
accomplished	O
with	O
a	O
Chromolith	O
Reversed	O
-	O
Phase	O
column	O
and	O
mobile	O
phases	I:C3469601
consisting	O
of	O
water	O
,	O
methanol	O
,	O
ammonium	B:C0051704
acetate	I:C0051704
and	O
formic	O
acid	I:C0016576
with	O
subsequent	O
mass	O
spectrometric	O
quantification	O
.	O

Simultaneous	O
separation	O
of	O
all	O
four	O
drugs	O
was	O
accomplished	O
with	O
a	O
Chromolith	O
Reversed	O
-	O
Phase	O
column	O
and	O
mobile	O
phases	I:C3469601
consisting	O
of	O
water	O
,	O
methanol	O
,	O
ammonium	O
acetate	I:C0051704
and	O
formic	B:C0016576
acid	I:C0016576
with	O
subsequent	O
mass	O
spectrometric	O
quantification	O
.	O

The	O
linear	O
range	O
of	O
the	O
calibration	O
curve	O
for	O
isoniazid	B:C0022209
was	O
0.5	O
-	O
10	O
mg	O
/L	O
,	O
for	O
rifampicin	O
0.75-30	O
mg	O
/L	O
,	O
for	O
ethambutol	O
0.25	O
-	O
10	O
mg	O
/	O
L	O
and	O
for	O
pyrazinamide	O
4	O
-	O
80	O
mg	O
/	O
L.	O

The	O
linear	O
range	O
of	O
the	O
calibration	O
curve	O
for	O
isoniazid	O
was	O
0.5	O
-	O
10	O
mg	O
/L	O
,	O
for	O
rifampicin	B:C0035608
0.75-30	O
mg	O
/L	O
,	O
for	O
ethambutol	O
0.25	O
-	O
10	O
mg	O
/	O
L	O
and	O
for	O
pyrazinamide	O
4	O
-	O
80	O
mg	O
/	O
L.	O

The	O
linear	O
range	O
of	O
the	O
calibration	O
curve	O
for	O
isoniazid	O
was	O
0.5	O
-	O
10	O
mg	O
/L	O
,	O
for	O
rifampicin	O
0.75-30	O
mg	O
/L	O
,	O
for	O
ethambutol	B:C0014964
0.25	O
-	O
10	O
mg	O
/	O
L	O
and	O
for	O
pyrazinamide	O
4	O
-	O
80	O
mg	O
/	O
L.	O

The	O
linear	O
range	O
of	O
the	O
calibration	O
curve	O
for	O
isoniazid	O
was	O
0.5	O
-	O
10	O
mg	O
/L	O
,	O
for	O
rifampicin	O
0.75-30	O
mg	O
/L	O
,	O
for	O
ethambutol	O
0.25	O
-	O
10	O
mg	O
/	O
L	O
and	O
for	O
pyrazinamide	B:C0034239
4	O
-	O
80	O
mg	O
/	O
L.	O

Precision	O
estimated	O
by	O
the	O
coefficient	O
of	O
variation	O
was	O
<	O
15	O
%	O
for	O
all	O
four	O
drugs	B:C0013227
.	O

The	O
LC	B:C0872318
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
can	O
readily	O
be	O
used	O
for	O
simultaneous	O
quantification	O
of	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	O
and	O
is	O
well	O
suited	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
.	O

The	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	B:C0037813
method	O
can	O
readily	O
be	O
used	O
for	O
simultaneous	O
quantification	O
of	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	O
and	O
is	O
well	O
suited	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
.	O

The	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
can	O
readily	O
be	O
used	O
for	O
simultaneous	O
quantification	O
of	O
first	O
-	O
line	O
anti-TB	B:C0003237
drugs	I:C0003237
in	O
plasma	O
and	O
is	O
well	O
suited	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
.	O

The	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
can	O
readily	O
be	O
used	O
for	O
simultaneous	O
quantification	O
of	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	B:C0032105
and	O
is	O
well	O
suited	O
for	O
therapeutic	O
drug	I:C1720825
monitoring	I:C1720825
.	O

The	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	O
method	O
can	O
readily	O
be	O
used	O
for	O
simultaneous	O
quantification	O
of	O
first	O
-	O
line	O
anti-TB	O
drugs	I:C0003237
in	O
plasma	O
and	O
is	O
well	O
suited	O
for	O
therapeutic	B:C1720825
drug	I:C1720825
monitoring	I:C1720825
.	O

